Answers are grounded in this paper and cite their sources.
Cancer-stem cells (or cancer-stem like cells, CSC) play an indispensable role in tumor initiation or tumor development in vivo. However, CSCs are resistant to conventional therapies including chemo/radiotherapy and a certain molecularly-targeted therapy, thereby are responsible for tumor relapse or metastasis in clinical settings. In this review, we focus on cytotoxic T-cell mediated immune responses against CSCs and discuss a challenge of targeting CSCs as well as the development of CSC-based cancer immunotherapy, which is an emerging and promising strategy toward a complete cure of quite a few types of cancers.
No takes yet. Share an insight, caveat, or question.
Miyamoto et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: